Atara Biotherapeutics, Inc. (ATRA)
| Market Cap | 70.99M +75.7% |
| Revenue (ttm) | 120.77M -6.3% |
| Net Income | 32.69M |
| EPS | 2.57 |
| Shares Out | 8.51M |
| PE Ratio | 3.25 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,874,487 |
| Open | 9.65 |
| Previous Close | 9.93 |
| Day's Range | 7.85 - 9.93 |
| 52-Week Range | 3.92 - 19.15 |
| Beta | -0.29 |
| Analysts | Hold |
| Price Target | 8.50 (+1.92%) |
| Earnings Date | May 13, 2026 |
About ATRA
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. T... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ATRA stock is "Hold." The 12-month stock price target is $8.5, which is an increase of 1.92% from the latest price.
News
Atara Biotherapeutics upgraded to Buy from Hold at Canaccord
Canaccord upgraded Atara Biotherapeutics (ATRA) to Buy from Hold with a price target of $13, up from $6. The type-A meeting with the FDA provides a potential approval pathway for
Atara Biotherapeutics trading halted, volatility trading pause
10:50 EDT Atara Biotherapeutics (ATRA) trading halted, volatility trading pause
Atara Biotherapeutics jumps 70%, or $3.60, to $8.75
10:51 EDT Atara Biotherapeutics (ATRA) jumps 70%, or $3.60, to $8.75
Atara Biotherapeutics trading resumes
10:55 EDT Atara Biotherapeutics (ATRA) trading resumes
Atara says PFP had productive meeting with FDA
Atara Biotherapeutics (ATRA) provided an update following the recent Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter to the Biologics License Applicat...
Why Is Atara Biotherapeutics Stock (ATRA) Up Today?
Atara Biotherapeutics stock was up on Thursday after the company received guidance from the FDA for a BLA resubmission.
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
NEW YORK, April 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Shareholders who purchased shares of ATRA during ...
ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 16, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NAS...
ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) investment, contact Lauren Molinaro of Kirby McIne...
Atara Biotherapeutics files to sell 400K shares of common stock for holders
The company will not receive any of the proceeds from the sale of its common stock by the selling stockholder.
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara provides update on tabelecleucel biologics license application
Atara Biotherapeutics (ATRA) announced that a Type A meeting with the FDA has been scheduled to discuss the complete response letter, or CRL, to the biologics license application for tabelecleucel
Atara Biotherapeutics partner submits Type A meeting request to FDA
Atara Biotherapeutics (ATRA) announced that its partner Pierre Fabre Pharmaceuticals has submitted a request to the FDA for a Type A meeting. Pierre Fabre Pharmaceuticals, in partnership with Atara, s...
Atara Biotherapeutics amends HealthCare Royalty purchase, sale agreement
Atara Biotherapeutics (ATRA) announced that the company entered into an amendment to the purchase and sale agreement dated as of December 20, 2022 with a fund managed by HealthCare Royalty.
Atara Biotherapeutics Provides a Business Update
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)
Canaccord earlier today downgraded Atara Biotherapeutics (ATRA) to Hold from Buy with a price target of $6, down from $25. The company announced receipt of a complete response letter from
FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form
Atara Biotherapeutics (ATRA) announced that the FDA has issued a complete response letter, or CRL, for the Ebvallo biologics license application as monotherapy treatment for adult and pediatric patien...
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears
Atara Biotherapeutics’ ($ATRA) shares glimmered on Thursday morning as investors anticipate the U.S. health watchdog will approve its living cell therapy. A decision on tabelecleucel is set to arrive ...
Atara Biotherapeutics price target raised to $25 from $17 at Canaccord
Canaccord raised the firm’s price target on Atara Biotherapeutics (ATRA) to $25 from $17 and keeps a Buy rating on the shares. The firm said they see a reasonable chance
Atara Biotherapeutics price target raised to $18 from $16 at Mizuho
Mizuho analyst Salim Syed raised the firm’s price target on Atara Biotherapeutics (ATRA) to $18 from $16 and keeps an Outperform rating on the shares. The firm said it raised
Atara Biotherapeutics price target raised to $140 from $131 at Mizuho
Mizuho analyst Salim Syed raised the firm’s price target on Atara Biotherapeutics (ATRA) to $140 from $131 and keeps an Outperform rating on the shares. The firm said it raised
Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)
Reports Q3 revenue $3.45M, consensus $2.74M. The company said, “As previously communicated, Atara continues to actively explore and assess potential strategic alternatives with the goal of maximizing ...
Atara Biotherapeutics reduces workforce by 29%
The company said, “In October 2025, Atara announced a reduction in its workforce that impacted approximately 29% of its current employees, retaining approximately 15 employees essential to executing o...